Genes associated with intestinal permeability in ulcerative colitis: Changes in expression following infliximab therapy

被引:38
作者
Toedter, Gary [1 ]
Li, Katherine [2 ]
Sague, Sarah [1 ]
Ma, Keying [1 ]
Marano, Colleen [3 ]
Macoritto, Michael [4 ]
Park, Jennifer [4 ]
Deehan, Renee [4 ]
Matthews, Andrea [4 ]
Wu, Gary D. [6 ]
Lewis, James D. [6 ]
Arijs, Ingrid [5 ]
Rutgeerts, Paul [5 ]
Baribaud, Frederic [1 ]
机构
[1] Centocor Res & Dev, Biomarkers, Malvern, PA USA
[2] Centocor Res & Dev, In Silico Immunol, Malvern, PA USA
[3] Clin Res & Dev Inc, Malvern, PA USA
[4] Selventa, Cambridge, MA USA
[5] Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA
[6] Univ Hosp Gasthuisberg, Dept Gastroenterol, B-3000 Louvain, Belgium
关键词
ulcerative colitis; infliximab; tight junction; epithelial-mesenchymal transition; INFLAMMATORY-BOWEL-DISEASE; EPITHELIAL TIGHT JUNCTIONS; CROHNS-DISEASE; CLAUDIN-2; EXPRESSION; TISSUE-INHIBITORS; RANDOMIZED-TRIAL; BARRIER FUNCTION; EPILYSIN MMP-28; MATRILYSIN; KEY;
D O I
10.1002/ibd.22853
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Alterations in intestinal permeability have been implicated in ulcerative colitis (UC). Infliximab, a monoclonal anti-tumor necrosis factor alpha (TNFa) antibody, can induce clinical response in UC. Gene expression in colonic biopsies taken from responders and nonresponders to infliximab can provide insight into the mechanisms of the altered intestinal permeability at a molecular level. Methods: Colonic biopsies (n = 18 anti-TNFa naive UC patients; n = 8 normal controls; n = 80 Active Ulcerative Colitis Trial [ACT] 1 patients) were analyzed for mRNA expression using gene expression microarrays. Computational reverse causal reasoning was applied to build causal network models of UC and response and nonresponse of UC to treatment. Quantitative reverse-transcription polymerase chain reaction (qPCR) was used to confirm differentially expressed genes. Results: Reverse causal reasoning on mRNA expression data from anti-TNFa-naive UC and normal samples provided a mechanistic disease model of the biology of gene expression observed in UC. mRNA expression data from the ACT 1 study enabled construction of a mechanistic model describing the biology of nonresponders to infliximab, including evidence for increased intestinal permeability compared with normal and responder samples. Gene expression changes identified as central to intestinal permeability dysregulation were confirmed in normal, UC, and infliximab-treated patients by qPCR analysis. Gene expression returned toward normal levels in infliximab responders, but not in nonresponders. Conclusion: Gene expression analysis and causal network modeling in combination showed that aberrant mRNA expression of genes involved in intestinal epithelial permeability for infliximab responders was restored toward levels observed in normal samples. Infliximab nonresponders showed no equivalent restoration in the expression of these genes. (Inflamm Bowel Dis 2012)
引用
收藏
页码:1399 / 1410
页数:12
相关论文
共 39 条
  • [1] Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells
    Amasheh, S
    Meiri, N
    Gitter, AH
    Schöneberg, T
    Mankertz, J
    Schulzke, JD
    Fromm, M
    [J]. JOURNAL OF CELL SCIENCE, 2002, 115 (24) : 4969 - 4976
  • [2] Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology
    Baumgart, Daniel C.
    Carding, Simon R.
    [J]. LANCET, 2007, 369 (9573) : 1627 - 1640
  • [3] A porous defense: the leaky epithelial barrier in intestinal disease
    Clayburgh, DR
    Shen, L
    Turner, JR
    [J]. LABORATORY INVESTIGATION, 2004, 84 (03) : 282 - 291
  • [4] Dudoit S, 2003, BIOTECHNIQUES, P45
  • [5] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Hanauer, SB
    Feagan, BG
    Lichtenstein, GR
    Mayer, LF
    Schreiber, S
    Colombel, JF
    Rachmilewitz, D
    Wolf, DC
    Olson, A
    Bao, WH
    Rutgeerts, P
    [J]. LANCET, 2002, 359 (9317) : 1541 - 1549
  • [6] Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution
    Heller, F
    Florian, P
    Bojarski, C
    Richter, J
    Christ, M
    Hillenbrand, B
    Mankertz, J
    Gitter, AH
    Bürgel, N
    Fromm, M
    Zeitz, M
    Fuss, I
    Strober, W
    Schulzke, JD
    [J]. GASTROENTEROLOGY, 2005, 129 (02) : 550 - 564
  • [7] Epilysin (MMP-28) - structure, expression and potential functions
    Illman, Sara A.
    Lohi, Jouko
    Keski-Oja, Jorma
    [J]. EXPERIMENTAL DERMATOLOGY, 2008, 17 (11) : 897 - 907
  • [8] Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
    Kumar, Rakesh
    Blakemore, Stephen J.
    Ellis, Catherine E.
    Petricoin, Emanuel F., III
    Pratt, Dexter
    Macoritto, Michael
    Matthews, Andrea L.
    Loureiro, Joseph J.
    Elliston, Keith
    [J]. BMC GENOMICS, 2010, 11
  • [9] Role of the intestinal barrier in inflammatory bowel disease
    Laukoetter, Mike G.
    Nava, Porfirio
    Nusrat, Asma
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (03) : 401 - 407
  • [10] Importance of Mucosal Healing in Ulcerative Colitis
    Lichtenstein, Gary R.
    Rutgeerts, Paul
    [J]. INFLAMMATORY BOWEL DISEASES, 2010, 16 (02) : 338 - 346